Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

769.30 +3.62 (+0.47%)
Streaming Delayed Price Updated: 3:47 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs. 
Via Stocktwits
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025 
Via MarketBeat
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Exposures Political
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
Via Benzinga
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal healing over two years. 
Via Benzinga
Exposures Product Safety
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors. 
Via The Motley Fool
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Via The Motley Fool
Topics Government
Exposures Political
9 of the 10 Largest Companies in the World Are Making Big Moves Into AI. Here's Why Investors Should Pay Attention.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Has Eli Lilly Stock Peaked?
Via The Motley Fool
My 10 Top Stocks to Buy to Start the New Year Off Right
Via The Motley Fool
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance. 
Via Benzinga
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
The company cut its fourth-quarter guidance by 5%. But there's still a lot happening for Lilly. 
Via Investor's Business Daily
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity. 
Via Stocktwits
Topics Earnings
Exposures Financial
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, Jan. 13, 2024 MSFT, APLD, RGTI, LLY, TSLA were among the stocks trending with investors. 
Via Benzinga
US Stocks Edge Higher As Traders Eye Inflation Data And Earnings Season Kickoff
Wall Street saw a modest uptick on Tuesday as investors turned their focus to upcoming US inflation data following a better-than-expected producer price index (PPI) report. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
A cooler-than-expected December producer inflation report failed to ignite lasting gains on Wall Street Tuesday, reflecting lingering concerns about persistently high inflation among investors. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections
The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches. 
Via Stocktwits
Topics Earnings
Exposures Financial
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. 
Via Investor's Business Daily
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and Zepbound. The 2025 outlook forecasts up to $61 billion. 
Via Benzinga
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down. 
Via MarketBeat
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline. 
Via Benzinga
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board Member
Moncton, New Brunswick, Canada--(Newsfile Corp. - January 13, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on... 
Via Newsfile
Exposures Lead
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
How Richard DiMarchi Revolutionized Diabetes Treatment
Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi. 
Via Investor's Business Daily
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.